3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
27
Neoplasms
3
Neoplasm Metastasis
3
Metastatic Castration-Resistant Prostate Cancer
3
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Hormone-sensitive Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Follicular
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Bites and Stings
1
Advanced Prostate Cancer
1
Adenocarcinoma
1
Interventions
Cisplatin
6
Paclitaxel
4
pembrolizumab
3
Fluorouracil
3
Carboplatin
3
tislelizumab
2
Taxes
2
Radiotherapy
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Injections
2
Capecitabine
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
lenvatinib
1
durvalumab
1
cixutumumab
1
apatinib
1
Tegafur
1
Surgical Procedures, Operative
1
Saline Solution
1
Radiation
1
Levoleucovorin
1
Laparoscopy
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Fulvestrant
1
Docetaxel
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
enzalutamide
×
30 days
×
Clear all
No trials found.